¾çµ¿¿ø ¸íÀÇ

´Ù¾çÇÑ Ä¡¸Å Ä¡·á Ȱ¾à ´º¿åŸÀÓÁîµµ ÁÖ¸ñ

¾çµ¿¿ø ¸íÀÇ

  • ¼Ò ¼Ó
    °¡Å縯´ë¼­¿ï¼º¸ðº´¿ø ½Å°æ°ú
  • Àü¹®ºÐ¾ß
    ±â¾ïÀå¾Ö ¹× Ä¡¸Å, ¾îÁö·³Áõ, µÎÅë

Àû±ØÀûÀ¸·Î Ä¡¸Å ¿¹¹æ ¿îµ¿¿¡ ³ª¼³ »Ó¸¸ ¾Æ´Ï¶ó ¿¬±¸¸¦ ÅëÇØ º¸´Ù È¿°úÀûÀÎ Ä¡¸Å Ä¡·á ¹æ¹ýÀ» °³¹ßÇϴµ¥ Èû¾²´Â ÀÇ»ç´Ù.
ÁÖ¿ä Áø·á ºÐ¾ß´Â ±â¾ïÀå¾Ö ¹× Ä¡¸Å, ¾îÁö·³Áõ, µÎÅëÀ¸·Î ¾ç ±³¼ö°¡ Ã¥ÀÓÀÚ·Î ÀÖ´Â ¸¶Æ÷±¸ Ä¡¸Å¼¾ÅÍ´Â Ä¡¸Å ȯÀÚ¸¦ À§ÇÑ ´Ù¾çÇÑ È°µ¿À» Àü°³Çϰí ÀÖ´Ù. Ȱµ¿ »ç·ÊµéÀº 2010³â, ¹Ì±¹ '´º¿åŸÀÓÁî'¿¡¼­ ½ÉÃþÀûÀ¸·Î ´Ù·ïÁ® È­Á¦°¡ µÇ±âµµ Çß´Ù. ±Ù·¡´Â Ä¡¸Å ȯÀÚ¿¡°Ô °æµÎ°³ÀÚ±âÀڱؼú(TMS)À» ½ÃÇàÇØ ÁÁÀº ¹ÝÀÀÀ» ¾ò°í ÀÖ´Ù. TMS´Â °íÁÖÆÄ ¶Ç´Â ÀúÁÖÆÄ Àü·ù¿¡¼­ ¹ß»ýÇÑ ÀÚ±âÀåÀ» ³ú¿¡ ½î¿© ³úÀÇ ½Å°æÀü´Þ¹°Áú ºÐºñ¸¦ ¹Ù·Î Àâ´Â Ä¡·á¹ýÀÌ´Ù. ÀÓ»ó½ÇÇèÀ» ÅëÇØ TMS°¡ ¾à¹°Ä¡·áº¸´Ù ºÎÀÛ¿ëÀÌ ÀûÀ¸¸ç Ä¡¸Å °°Àº ³ú½Å°æ Áúȯ Ä¡·á¿¡ ¶Ù¾î³­ È¿°ú¸¦ ³ªÅ¸³½´Ù´Â »ç½ÇÀ» ÀÔÁõÇß´Ù. 2002³â¿¡´Â Ä¡¸ÅÇÐȸ ÃÖ¿ì¼ö ³í¹®»óÀ» ¼ö»óÇßÀ¸¸ç, 2015³â ´ëÇÑÀÇÇÐȸ °¡¼ÛÀÇÇлóÀ» ¼ö»óÇß´Ù.

¸íÀÇÇÁ·ÎÇÊ ¸íÀÇ ÇÁ·ÎÇÊ

ÇзÂ

Educational Background
  • °¡Å縯´ë ÀÇ´ë Çлç
  • °¡Å縯´ë ÀÇ´ë ¼®»ç
  • °¡Å縯´ë ÀÇ´ë ¹Ú»ç

ÁÖ¿ä°æ·Â

Work Experience
  • úÞ) °¡Å縯´ë¼­¿ï¼º¸ðº´¿ø ½Å°æ°ú ±³¼ö
  • úÞ) Áß¾Ó¿¬±¸À±¸®»ç¹«±¹ ±¹Àå
  • úÞ) ¸¶Æ÷±¸Ä¡¸ÅÁö¿ø¼¾ÅÍ ¼¾ÅÍÀå

¼ö»ó³»¿ª

Awards List
  • ´ëÅë·É»ó : Ä¡¸Å ¿¹¹æ°ú ȯÀÚÀÇ °ü¸® (2022)
  • ´ëÇÑÄ¡¸ÅÇÐȸ ¿ì¼ö ±¸¿¬¹ßÇ¥»ó Validity of CT based SUVR for the semi-quantitative analysis of amyloid PET in SCD (2021)
  • º¸°Çº¹ÁöºÎÀå°ü»ó : Ä¡¸Å¿¹¹æ°ú Ä¡¸ÅȯÀÚÀÇ °ü¸® (2019)
  • °¡Å縯´ëÇб³ ´ëÇпø ¿ì¼ö³í¹®»ó (2016)
  • °¡¼ÛÀÇÇлó¼ö»ó - ´ëÇÑÀÇÇÐȸ ±¹Á¦ Àú³ÎÀÎ (2015)
  • º¸°Çº¹ÁöºÎÀå°ü»ó : Ä¡¸Å¿¹¹æ°úÄ¡¸ÅȯÀÚÀÇ °ü¸® (2012)
  • ´ëÇѽŰæ°úÇÐȸ ¿ì¼ö¿¬Á¦»ó (2009)

ÇÐȸȰµ¿

Academic activities
  • 2020 ~ ÇöÀçÀÎÁöÁßÀçÄ¡·áÇÐȸ ȸÀå
  • 2020 ~ ÇöÀç´ëÇÑÄ¡¸ÅÇÐȸ ÀÌ»çÀå
Àú¼­ ¾ÆÀÌÄÜ

ÁýÇÊÀú¼­

ÃÑ 5°Ç
Á¦ ¸ñ Ä¡¸ÅÀÇ ½Å°æÇൿÁõ»ó
ÃâÆÇ»ç ´ëÇÑÀÇÇÐ ¹ßÇàÀÏ 2017
Á¦ ¸ñ Amyloid PET Neuroimaging
ÃâÆÇ»ç ¸ÞµðÄ®¾÷Àú¹ö ¹ßÇàÀÏ 2017
Á¦ ¸ñ Memantine from basic research to Clinical Practice-2nd editioin
ÃâÆÇ»ç ¸ÞµðÄ®¾÷Àú¹ö ¹ßÇàÀÏ 2015
Á¦ ¸ñ ½Å°æ¡¤Á¤½ÅÀÇÇÐÀÇ ³ú°úÇÐ
ÃâÆÇ»ç ±ºÀÚÃâÆÇ»ç ¹ßÇàÀÏ 2013
Á¦ ¸ñ Memantine from basic research to clinical practice -1st edition
ÃâÆÇ»ç ¸ÞµðÄ®¾÷Àú¹ö ¹ßÇàÀÏ 2013
¿¬±¸ ¾ÆÀÌÄÜ

ÁÖ¿ä³í¹®

ÃÑ 5°Ç
Á¦ ¸ñ Clinical Significance of Physical Frailty in Subjects With Subjective Cognitive Decline: A Prospective Study With Amyloid PET Data
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö JOURNAL OF CLINICAL NEUROLOGY
Á¦ ¸ñ Impacts of baseline biomarkers on cognitive trajectories in subjective cognitive decline: the CoSCo prospective cohort study
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö ALZHEIMERS RESEARCH & THERAPY
Á¦ ¸ñ A Multicentre, Randomised, Open-Label, Prospective Study to Estimate the Add-On Effects Of Memantine as Ebixa?? Oral Pump (Solution) on Language in Patients with Moderate to Severe Alzheimer's Disease Already Receiving Donepezil (ROMEO-AD)
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö NEUROLOGY AND THERAPY
Á¦ ¸ñ PET-validated EEG-machine learning algorithm predicts brain amyloid pathology in pre-dementia Alzheimer's disease
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö SCIENTIFIC REPORTS
Á¦ ¸ñ Development of a home-based cognitive test for cognitive monitoring in subjective cognitive decline with high risk of Alzheimer's disease
¹ßÇ¥³âµµ 2023 ¹ßÇ¥Áö MEDICINE

¸íÀÇqna ¸íÀÇ ¼Ò¼Óº´¿ø

°¡Å縯´ë¼­¿ï¼º¸ðº´¿ø

»ó±ÞÁ¾ÇÕº´¿ø
ÀüÈ­ ¾ÆÀÌÄÜ ´ëÇ¥¹øÈ£
1588-1511
À¥»çÀÌÆ® ¾ÆÀÌÄÜȨÆäÀÌÁö

ÁÖ¿ä½Ã¼³

ÀÀ±Þ½Ç ÀÀ±Þ½Ç
Ŭ¸®´Ð Ŭ¸®´Ð
Á¾ÇÕ°ËÁø¼¾ÅÍ Á¾ÇÕ°ËÁø¼¾ÅÍ
¾Ï¼¾ÅÍ ¾Ï¼¾ÅÍ
ÁÖÂ÷½Ã¼³ ÁÖÂ÷½Ã¼³

°¡Å縯´ë¼­¿ï¼º¸ðº´¿øÀº 1980³â °­³² Áö¿ª ÃÖÃÊÀÇ Á¾ÇÕº´¿øÀ¸·Î ¼¼¿öÁ³´Ù. ÇöÀç Áö»ó 22Ãþ, ÁöÇÏ 6ÃþÀÇ 1355º´»ó ±Ô¸ð¸¦ °®Ãß°í ÀÖÀ¸¸ç ´ÜÀÏ °Ç¹° º´¿øÀ¸·Î´Â ±¹³» ÃÖ´ë ±Ô¸ðÀÌ´Ù. °¡Å縯´ë¼­¿ï¼º¸ðº´¿øÀº °¡Å縯±³È¸ÀÇ ´ëÇ¥ º´¿øÀ¸·Î °¡Å縯Áß¾ÓÀÇ·á¿øÀÇ ÀÌ³ä ½Çõ¿¡ Àû±Ø ¾ÕÀå¼­°í ÀÖÀ¸¸ç, ȯÀÚ¸¦ ¸ÕÀú »ý°¢ÇÏ´Â Àü¹®¼¾ÅÍ Áß½ÉÀÇ º´¿ø, 21¼¼±â ÃÖ÷´Ü ÀÇ·á ½Ã½ºÅÛ º´¿øÀ¸·Î °Åµì³ª°í ÀÖ´Ù.

°¡Å縯´ë¼­¿ï¼º¸ðº´¿ø À̹ÌÁö

¼­¿ïƯº°½Ã ¼­Ãʱ¸ ¹ÝÆ÷´ë·Î 222

Ȩ
³»°¡ ¾Ë°íÀÖ´Â ¸íÀǸ¦ ÃßÃµÇØÁÖ¼¼¿ä